KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Travere Therapeutics (TVTX) Income from Continuing Operations: 2011-2024

Historic Income from Continuing Operations for Travere Therapeutics (TVTX) over the last 14 years, with Dec 2024 value amounting to -$320.6 million.

  • Travere Therapeutics' Income from Continuing Operations rose 146.95% to $25.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$88.5 million, marking a year-over-year increase of 74.63%. This contributed to the annual value of -$320.6 million for FY2024, which is 14.80% up from last year.
  • Latest data reveals that Travere Therapeutics reported Income from Continuing Operations of -$320.6 million as of FY2024, which was up 14.80% from -$376.3 million recorded in FY2023.
  • Travere Therapeutics' Income from Continuing Operations' 5-year high stood at -$169.4 million during FY2020, with a 5-year trough of -$376.3 million in FY2023.
  • Over the past 3 years, Travere Therapeutics' median Income from Continuing Operations value was -$331.5 million (recorded in 2022), while the average stood at -$342.8 million.
  • In the last 5 years, Travere Therapeutics' Income from Continuing Operations tumbled by 52.54% in 2022 and then climbed by 14.80% in 2024.
  • Over the past 5 years, Travere Therapeutics' Income from Continuing Operations (Yearly) stood at -$169.4 million in 2020, then fell by 28.25% to -$217.3 million in 2021, then tumbled by 52.54% to -$331.5 million in 2022, then declined by 13.54% to -$376.3 million in 2023, then increased by 14.80% to -$320.6 million in 2024.